Neuralstem (CUR) Receives Daily Media Sentiment Rating of 0.09
News stories about Neuralstem (NASDAQ:CUR) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Neuralstem earned a coverage optimism score of 0.09 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 47.0380005563562 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Shares of Neuralstem (NASDAQ:CUR) opened at $1.10 on Friday. Neuralstem has a fifty-two week low of $0.88 and a fifty-two week high of $6.60.
Neuralstem Company Profile
Neuralstem, Inc (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform.
Receive News & Ratings for Neuralstem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.